cant bimodal distribution in the sample, with an SZ subgroup expressing significantly greater levels of activated pSTAT1 than the remainder of the participants. In this subgroup, levels of pSTAT1 were significantly higher than in the control group, as well as significantly higher than in the remainder of the SZ subjects. Furthermore, this subsample of patients manifested significantly poorer cognitive performance on several measures of the MATRICS. Discussion: pSTAT1 levels may provide a measure of the biological relevance of widely reported elevations in levels of cytokines in SZ over the past several decades. Activation of kinase cascades can be used to partition or disassemble the composite immune signal in patients living with SZ.
Introduction
A subclinical immunoreactive state, broadly characterized by elevated levels of serum/plasma cytokines, as well as several parameters of immune cellular functioning, has been widely reported in schizophrenia (SZ) subjects [1, 2] . Genetic genome-wide association studies [3] and an increased prevalence of autoimmune conditions in the disorder [4, 5] have provided further support for the role of immunoreactivity in SZ. However, there is substantial variability in the published findings, which could be due to the multiple sources that contribute to blood cytokine levels, such as adipose tissue, liver and muscle. There is also no clear understanding of the biological impact of these subclinical elevated levels of cytokine proteins in participants with SZ.
STAT1 is a member of the signal transducer and activator of transcription (STAT) family of transcription factors, capable of carrying a signal from a membrane receptor directly to the nucleus and a DNA cognate sequence. STAT proteins are dormant in the cytoplasm until activated by tyrosine phosphorylation. Multiple signals can activate phosphorylated STAT1 (pSTAT1) using the JAK/STAT axis, including growth factors (EFG), cytokines (IFNγ, IL6, IL2, IL3, IL12 and IL22) and hypoxia [6, 7] . Cytokine receptors of the type gp130 and IFNGR are associated with JAK kinases that induce tyrosine phosphorylation of cytoplasmic STAT1 (Y701), and pSTAT1 is especially strongly activated in CD14+ monocytes stimulated with IFNγ or IFNα [8] . Because a given cell can integrate cytokine signals from multiple pathways, different cytokines such as IFNγ and IL6 (often implicated in SZ) can both induce STAT1 activation upon binding to their specific membrane receptors [9] . A recurrent theme in SZ research is the coordination of increased immunoreactivity (measured by serum cytokine levels) and cognitive measures [10] .
Levels of pSTAT1 can be measured using biochemical methods in peripheral blood mononuclear cells (PBMCs), as demonstrated by a number of previously published studies on humans. These include the measurement of immune states in rheumatoid arthritis (IL6) [11] as well as in response to corticosteroids in active asthma [12] and to cytokines in hepatitis C (IFNα) [8] . We hypothesized that measurement of an intracellular signaling pathway downstream of a cytokine receptor could aggregate the inputs of multiple immune stimuli and provide a more consistent measure of immune activation in peripheral blood samples. This study reports the analyses for a novel investigation into the molecular, clinical and cognitive interface.
Methods

Subject Recruitment
Subjects were recruited from the University of Illinois at Chicago (UIC) Medical Center and surrounding urban community mental health clinics. The study was approved by the UIC Institutional Review Board and all subjects provided written informed consent before participating in any study procedures. General exclusion criteria for all subjects were: (1) reported infections, (2) neurological disease or head trauma, (3) current substance dependence, (4) substance abuse/dependency within the past 2 months and (5) pregnancy. Diagnosis was established using an SCID/DSM-IV interview [13] and available collateral information. Illicit substance use was obtained as part of the SCID diagnostic interview, but we did not apply urine toxicology. The nonclinical control sample consisted of individuals who did not meet the criteria for current or past psychiatric diagnosis as evaluated by the SCID/DSM-IV. Clinical symptomology was measured using the Positive and Negative Syndrome Scale (PANSS), and cognition was measured using the MATRICS Consensus Cognitive Battery [14, 15] .
Subjects
A total of 35 subjects participated in the study, 22 with SZ (17 males and 5 females) and 13 controls, i.e. with no major Axis 1 disorder (5 males and 8 females). Of the 22 SZ participants, 16 were evaluated at the inpatient psychiatric unit and the other 6 in the outpatient clinic. The mean duration of illness in the SZ group was 20 years. Additionally, 11/22 participants with SZ reported nicotine use compared to 5/13 controls. Out of the 22 participants with SZ, 19 were reported as being on atypical antipsychotic medication, 3 as taking typical antipsychotic medication and 1 as being unmedicated at the time of the blood draw. No control subjects reported taking any antipsychotic medications. In addition, no relationship was found between the pSTAT1 levels and the CPZ equivalents of these medications [16, 17] . Furthermore, we cannot easily ascertain the duration of pharmacological treatment due to multiple changes in psychotropic regimens that are difficult and unreliable to track, but if we approximate this parameter using 'duration of the illness', we do not observe a significant relationship.
PBMC Collection
All peripheral blood sample collections were performed under nonfasting conditions in the early morning between 07: 00 and 09: 00 h to avoid circadian fluctuations. PBMCs were extracted using standard Ficoll gradients [18, 19] .
Nuclear Protein Extraction and Measurement
Nuclear protein extraction was performed as previously published [20] and protein levels were quantified using the Bradford method.
The pSTAT1 modification was measured utilizing the enzymelinked immunosorbent assay (ELISA) kit commercially available from Abcam (No. 126456). Levels of total histone 3 (H3) protein for each sample were also measured for normalization purposes using an aliquot of the identical sample utilized for the pSTAT1 modification. Total H3 protein was measured using the ActiveMotif (No. 53110) kit as previously described [21] .
Clinical Measures
The primary clinical measures for this study were the Positive and Negative Syndrome Scale (PANSS) and the MATRICS Consensus Cognitive Battery [14, 15] . PANSS items were scored along a continuum of severity from 1 (asymptomatic) to 7 (extreme symptom severity). The α coefficient for interrater reliability was 226 between 0.83 and 0.87. With regard to the MATRICS, we analyzed the cognitive domain scores (rather than the individual test scores), which are considered a composite and reliable assessment of particular cognitive abilities [22] [23] [24] . These 6 domain scores include Processing Speed, Attention, Working Memory, Verbal Memory, Visual Memory and Reasoning.
Statistical Analysis SPSS (v15.0 for Windows) was used for all statistical analyses. Data are presented as mean values ± standard error. A probability level p < 0.05 was the criterion to achieve statistical significance. Demographic and clinical data were analyzed by using the χ 2 test and analysis of variance (ANOVA). The Scheffé post hoc test was used to identify significant pair-wise group differences. Bimodality was tested assuming mixtures of normal distributions [25, 26] .
Results
Descriptive Demographics
We found no significant effect of age, sex, race or BMI on pSTAT1 levels ( table 1 ). There was no significant difference between groups regarding nicotine use. Additionally, there was no significant difference in duration of illness between the subjects with a low pSTAT1 level, i.e. the SZ-LOW group, and those with an elevated pSTAT1 level, i.e. the SZ-HIGH group. We also found no effect of length of sample storage time or number of freeze-thaw events. There were no significant differences in total H3 levels between controls and participants with SZ.
Bimodal Distribution and Diagnostic Differences
There was a trend towards increased pSTAT1 levels when comparing the control (n = 13) and SZ (n = 22) groups (0.1431 vs. 0.2330, d.f. 33; p < 0.09). However, as seen in figure 1 a, the data suggested a bimodal distribution within the group of participants with SZ, so bimodality was tested assuming a mixture of 2 normal distributions [25, 26] . The samples from participants with SZ had a significantly bimodal distribution (μ1 = 0.015, σ1 = 0.124; μ2 = 0.310, σ2 = 0.206; p < 0.001). Data were then analyzed based on this result, and participants with SZ with a measurement above the μ2 = 0.310 value were coded as having high pSTAT1 activation while the remainder of the SZ sample was coded as having low pSTAT1 activation (μ2 < 0.310). As noted in table 1 , there was no significant difference in gender, race or age between groups.
We were thus able to characterize the participants as 3 groups: control (CON)-LOW (μ2 < 0.310), SZ-LOW (μ2 < 0.310) and SZ-HIGH (μ2 ≥ 0.310). Levels of pSTAT1 were then analyzed using a one-way ANOVA ( fig. 1 b) . In the SZ-HIGH subgroup, levels of pSTAT1 were 69% higher than in the CON-LOW subjects, and 62% higher than in the SZ-LOW subjects ( table 1 ) .
Clinical and Cognitive Correlations
Our primary objective was to distinguish SZ subjects according to whether they had activated pSTAT1 or not, i.e. subjects designated as SZ-HIGH versus SZ-LOW. An ANOVA with the post hoc Scheffé test, found that the total PANSS score, as a measure of psychopathology, was virtually identical in the 2 SZ groups (104.54 vs. 104.44) and that both were significantly higher than the control group (34.92). Furthermore, a t test indicated that there were no significant differences between the SZ-HIGH and SZ-LOW groups on the PANSS positive, negative or general subscales. There was also no significant correlation between pSTAT1 levels and PANSS scores in the SZ-HIGH group. To continue this focus of analysis in the area of cognition, we initially compared all low-and high-pSTAT1 subjects according to the 6 domain scores. Processing Speed (t = 2.2; p < 0.01) and Attention (t = 2.3; p < 0.03) were significantly worse in subjects with high pSTAT1 when compared to all subjects with a low pSTAT1 (CON-LOW + SZ-LOW). To identify the cognition correlates of high pSTAT1 in the SZ subgroups, we next performed an ANOVA with the 3 groups, CON-LOW, SZ-LOW and SZ-HIGH, on the 6 domains. Attention and Reasoning were significantly lower in the SZ-HIGH group than in either of the low groups, i.e. the CON-LOW and SZ-LOW groups ( fig. 2) . SZ-HIGH participants scored significantly worse on both the Attention (p < 0.01) and Reasoning (p < 0.04) scores than either the CON-LOW or SZ-LOW groups, but there was no difference in the SZ-LOW and CON-LOW group on either score. A similar trend was observed for Processing Speed, but did not reach significance. Thus, SZ-HIGH subjects showed a poorer performance on these specific cognitive measures than the remainder of the sample. Though these particular cognitive measures were significantly worse in the SZ-HIGH group, we did not demonstrate a correlation between pSTAT1 levels and MATRICS domain scores.
Discussion
Given the known heterogeneity of the SZ diagnosis, as well as the multiple sources of immunoreactivity, the presence of a subgroup of participants with SZ with a heightened level of pSTAT1 in their nuclear protein extracts may not be surprising, but remains an intriguing finding. The presence of the CON-LOW group and the SZ-LOW group provided a naturalistic subject comparison to further be able to distinguish SZ subjects with high pSTAT1 activation.
STAT1 is phosphorylated by the JAK/STAT cascade emanating from membrane cytokine receptors that are targets of proinflammatory cytokines such as IFNγ and Fig. 1 . a Scatterbar plot of controls and all SZ subjects on measures of pSTAT1 normalized to total H3 protein from nuclear extracts in PBMCs. There was no significant difference (p < 0.09) between the controls and the SZ group. b The SZ participants were divided with a significant bimodal distribution (as noted in the Results) into the SZ-LOW and SZ-HIGH groups.
Box-whisker plots demonstrate the median of the 3 groups. There was no significant difference between the CON-LOW and SZ-LOW groups. IL6. These cytokines are elevated in SZ, as summarized in several meta-analyses [1, 2] . As an example, IFNγ will induce STAT1 activation and sustained occupancy of the pSTAT1 cistrome [27, 28] , resulting in further upregulation of additional proinflammatory cytokines such as TNFα, IL6 and IL12. pSTAT1 occupancy of its cistrome is facilitated by epigenetic chromatin modifications resulting in accessible chromatin [29, 28] . This is consistent with our recent report of elevated H3 phosphorylated at serine 10 [21] in PBMCs from patients with SZ. Furthermore, activation of the pSTAT1 pathway by IFNγ or IL6 can upregulate the expression of Toll-like receptors (TLRs) in a variety of immune cells including monocytes [30, 31] , and can, consequently, prime these cells to amplify signals along the NF-κB pathway. TLR signals emanate from exogenous and endogenous TLR ligands, which are comprised of bacterial elements (lipopolysaccharides) as well as complexes of fatty acids and acute reactive proteins [32] , resulting in what is sometimes termed 'sterile' inflammation.
CON-LOW
Associations between immune functioning and cognition are increasingly reported. In rodents, increases in peripheral proinflammatory cytokines can induce changes in immune signaling in the hippocampus [33] . Recently, Fillman et al. [34] also identified a subgroup of patients with SZ who had elevated cytokines and demonstrated decreases in cognition (Verbal Fluency) combined with decreases in specific brain volume. Specifically, elevated IL1β significantly predicted lower scores in Verbal Fluency. Another study, using plasma from patients with firstepisode psychosis, found that the expression of MCP-1, a chemokine involved in the initiation of the inflammatory process, was negatively correlated with learning and memory measures [35] . Furthermore, a recent analysis of transcriptomic data from PBMCs of patients with SZ and healthy controls found altered expression of genes in the antigen presentation pathway that was more pronounced in patients with cognitive deficits than in those with no such deficits and in the healthy controls [36] .
The main limitation of this study is clearly the small sample size, particularly the limited number of subjects in the SZ-HIGH group. Other limitations include the absence of serum levels of cytokines to contextualize the immune environment. Finally, the use of PBMCs does not allow us to focus the findings in a given peripheral blood cell type, a process that would be best accomplished using flow cytometry.
A subclinical inflammatory state characterized by chronically elevated proinflammatory cytokines is a perennial finding in SZ. The intracellular events that result from this endogenous cytokine production have not been studied in SZ. The results reported here provide a strategy to pursue these signals into the cell, and because intracellular phosphorylation pathways serve as aggregators of composite incoming stimuli, they could be used to identify the downstream target of immunoreactive stimuli such as bacterial infections, adiposity, pharmacology and drugs of abuse.
